Trial intelligence / Profile preview

KEYNOTE-B96 / ENGOT-ov65 in platinum-resistant recurrent ovarian cancer

NL-OMON51981Phase 3Recruiting

Sponsor: Merck & Co.
Start: Mar 2022
Modality: Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
Countries: 1

Overview

Phase 3, randomised, double-blind trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing Pembrolizumab + paclitaxel with or without bevacizumab with Placebo + paclitaxel with or without bevacizumab (2 arms). Primary endpoint: Progression-free survival. Started Mar 2022; status: recruiting.

Drugs

pembrolizumabpaclitaxelbevacizumab

Conditions

ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)

Beyond the preview

Go deeper on NL-OMON51981.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NL-OMON51981.